Navigation Links
Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions

A novel anti-clotting drug named bivalirudin is turning out to be a better option than combination drug therapy for patients suffering heightened //coronary conditions, for instance heart attacks.

Lead researcher Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education at Columbia University said, "We use it at Columbia in the vast majority of cases. We find that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

During a study involving 14,000 patients, who had suffered heart attack or other acute coronary syndromes, study participants were administered either a treatment including heparin, or a package including bivalirudin or just bivalirudin.It was found that Bivalrudin reduced the occurrence of artery blockage or severe bleeding by nearly 14 percent compared to the effects of a drug package that included Heparin.

"It makes care of patients in the cath lab much simpler and safer. The big difference was the reduction of major bleeding, almost 50 percent. Major bleeding has been associated with higher mortality, so it is important for the outcome", Dr. Gregg W. Stone said.

Dr. John A. Bittl, an interventional cardiologist at the Munroe Regional Medical Center in Ocala, commented, "This report states that bivalirudin can be used for patents with acute coronary syndrome with a lower risk of bleeding than conventional treatment."
'"/>




Page: 1

Related medicine news :

1. Enduring anti-clotting treatment avails heart patients
2. Useful device makes spinal surgery safer
3. Transporter offers reliable clues for safer pain medicine
4. Arthritis drugs safer than previously declared
5. Diet and exercise can be a better option to control diabetes
6. Early detection of alcohol abuse is better option for treatment
7. Children obesity has an option in the form of surgery
8. Substituting soymilk for lactose intolerant students n schools: a great option
9. To cope better with HRT, a good option is Hysterectomies
10. Sweet nothings: A fruitful option to assuage the sweet tooth
11. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... Oregon (PRWEB) , ... March 27, 2017 , ... ... is pleased to announce the launch of a months-long rebranding effort. This includes ... formulations. , “Through focus group discussions and market research, we learned that a ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... The homeowner ... the number of homeowners utilizing DIY and unlicensed contractors for renovations is also on ... or replacement project in 2015, and of those, 42% failed to use a licensed ...
(Date:3/25/2017)... ... ... Norland at Swissray is pleased to announce the release of the ELITE DXA, a ... an active scan window, which is more than double that of existing bone densitometers. ... not undergo an accurate total body bone density or body composition study. The ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... third world countries to hospitals in the United States, it’s a threat that ... the current obstacles facing infection prevention and offers strategies for the healthcare community ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... at 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio ... Ali Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
Breaking Medicine Technology: